Aktis Oncology (NASDAQ:AKTS) Hits New 1-Year Low – Here’s Why

Aktis Oncology (NASDAQ:AKTS)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $19.02 and last traded at $20.50, with a volume of 323657 shares changing hands. The stock had previously closed at $21.35.

Aktis Oncology Stock Performance

Insider Activity

In other Aktis Oncology news, Director Helen Susan Kim acquired 835,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the acquisition, the director directly owned 5,671,825 shares in the company, valued at $102,092,850. This represents a 17.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the acquisition, the insider directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. The trade was a 17.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 6,117,776 shares of company stock valued at $110,119,968. 3.30% of the stock is currently owned by company insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.